Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Aydinok, Yesim, Kattamis, Antonis, Cappellini, M. Domenica, El-Beshlawy, Amal, Origa, Raffaella, Elalfy, Mohsen, Kilinç, Yurdanur, Perrotta, Silverio, Karakas, Zeynep, Viprakasit, Vip, Habr, Dany, Constantinovici, Niculae, Shen, Junwu, Porter, John B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490296/
https://ncbi.nlm.nih.gov/pubmed/25934475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-586677
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados